Physiology and pathophysiology of iron in hemoglobin-associated diseases

Free Radical Biology and Medicine

Volumn 72, Issue , 2014, Pages 23-40

  Coates, Thomas D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chelation; Hemochromatosis; Hemoglobinopathy; Iron overload; Iron toxicity; Magnetic resonance imaging; ROS; Sickle cell disease; Thalassemia; Transfusion

Indexed keywords

FERRITIN; FERROPORTIN; HEPCIDIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG; HEMOGLOBIN; IRON CHELATING AGENT;

ANEMIA; CHELATION THERAPY; CLINICAL OBSERVATION; CONGENITAL DYSERYTHROPOIETIC ANEMIA; ERYTHROCYTE; ERYTHROPOIESIS; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEMOGLOBIN ASSOCIATED DISEASE; HOMEOSTASIS; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON BLOOD LEVEL; IRON OVERLOAD; IRON TRANSPORT; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; SIDEROBLASTIC ANEMIA; THALASSEMIA; HEMOGLOBINOPATHIES; METABOLISM;

HEMOGLOBINOPATHIES; HEMOGLOBINS; HOMEOSTASIS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 84899803096     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.03.039     Document Type: Review

References (242)

1. V. Berdoukas, K. Farmaki, S. Carson, J. Wood, and T. Coates Treating thalassemia major-related iron overload: the role of deferiprone J. Blood Med. 3 2012 119 129
2. B. Modell, M. Khan, M. Darlison, M.A. Westwood, D. Ingram, and D.J. Pennell Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance J. Cardiovasc. Magn. Reson. 10 2008 42
3. R. Green, R. Charlton, H. Seftel, T. Bothwell, F. Mayet, B. Adams, C. Finch, and M. Layrisse Body iron excretion in man: a collaborative study Am. J. Med. 45 1968 336 353
4. T. Ganz Systemic iron homeostasis Physiol. Rev. 93 2013 1721 1741
5. D.M. Frazer, and G.J. Anderson The regulation of iron transport BioFactors 40 2 2014 206 214
6. C.P. Anderson, M. Shen, R.S. Eisenstein, and E.A. Leibold Mammalian iron metabolism and its control by iron regulatory proteins Biochim. Biophys. Acta 1823 2012 1468 1483
7. M. Sanchez, B. Galy, M.U. Muckenthaler, and M.W. Hentze Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency Nat. Struct. Mol. Biol. 14 2007 420 426
8. M.W. Hentze, and L.C. Kuhn Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress Proc. Natl. Acad. Sci. USA 93 1996 8175 8182
9. H. Nam, C.Y. Wang, L. Zhang, W. Zhang, S. Hojyo, T. Fukada, and M.D. Knutson ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders Haematologica 98 2013 1049 1057
10. P.L. Lee, T. Gelbart, C. West, C. Halloran, and E. Beutler The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms Blood Cells Mol. Dis. 24 1998 199 215
11. M. Sanchez, B. Galy, B. Schwanhaeusser, J. Blake, T. Bahr-Ivacevic, V. Benes, M. Selbach, M.U. Muckenthaler, and M.W. Hentze Iron regulatory protein-1 and -2: transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins Blood 118 2011 e168 e179
12. H. Gunshin, B. Mackenzie, U.V. Berger, Y. Gunshin, M.F. Romero, W.F. Boron, S. Nussberger, J.L. Gollan, and M.A. Hediger Cloning and characterization of a mammalian proton-coupled metal-ion transporter Nature 388 1997 482 488
13. G.J. Anderson, D.M. Frazer, and G.D. McLaren Iron absorption and metabolism Curr. Opin. Gastroenterol. 25 2009 129 135
14. M. Shayeghi, G.O. Latunde-Dada, J.S. Oakhill, A.H. Laftah, K. Takeuchi, N. Halliday, Y. Khan, A. Warley, F.E. McCann, R.C. Hider, D.M. Frazer, G.J. Anderson, C.D. Vulpe, R.J. Simpson, and A.T. McKie Identification of an intestinal heme transporter Cell 122 2005 789 801
15. A. Donovan, C.N. Roy, and N.C. Andrews The ins and outs of iron homeostasis Physiology (Bethesda) 21 2006 115 123
16. C. Beaumont, and F. Canonne-Hergaux [Erythrophagocytosis and recycling of heme iron in normal and pathological conditions; regulation by hepcidin] Transfus. Clin. Biol. 12 2005 123 130
17. M. Kristiansen, J.H. Graversen, C. Jacobsen, O. Sonne, H.J. Hoffman, S.K. Law, and S.K. Moestrup Identification of the haemoglobin scavenger receptor Nature 409 2001 198 201
18. T. Ganz, and E. Nemeth Regulation of iron acquisition and iron distribution in mammals Biochim. Biophys. Acta 1763 2006 690 699
19. K.D. Poss, and S. Tonegawa Heme oxygenase 1 is required for mammalian iron reutilization Proc. Natl. Acad. Sci. USA 94 1997 10919 10924
20. J.C. Deschemin, and S. Vaulont Role of hepcidin in the setting of hypoferremia during acute inflammation PLoS One 8 2013 e61050
21. M. Hoppe, and L. Hulthen Capturing the onset of the common cold and its effects on iron absorption Eur. J. Clin. Nutr. 61 2007 1032 1034
22. E. Tolosano, S. Fagoonee, N. Morello, F. Vinchi, and V. Fiorito Heme scavenging and the other facets of hemopexin Antioxid. Redox Signaling 12 2010 305 320
23. P. Ascenzi, A. Bocedi, P. Visca, F. Altruda, E. Tolosano, T. Beringhelli, and M. Fasano Hemoglobin and heme scavenging IUBMB Life 57 2005 749 759
24. G.J. Anderson, and D.M. Frazer Hepatic iron metabolism Semin. Liver Dis. 25 2005 420 432
25. F. Canonne-Hergaux, A.S. Zhang, P. Ponka, and P. Gros Characterization of the iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice Blood 98 2001 3823 3830
26. H. Gunshin, C.R. Allerson, M. Polycarpou-Schwarz, A. Rofts, J.T. Rogers, F. Kishi, M.W. Hentze, T.A. Rouault, N.C. Andrews, and M.A. Hediger Iron-dependent regulation of the divalent metal ion transporter FEBS Lett. 509 2001 309 316
27. L.A. Cohen, L. Gutierrez, A. Weiss, Y. Leichtmann-Bardoogo, D.L. Zhang, D.R. Crooks, R. Sougrat, A. Morgenstern, B. Galy, M.W. Hentze, F.J. Lazaro, T.A. Rouault, and E.G. Meyron-Holtz Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway Blood 116 2010 1574 1584
28. P. Ponka Rare causes of hereditary iron overload Semin. Hematol. 39 2002 249 262
29. M. Puliyel, R. Sposto, V.A. Berdoukas, T.C. Hofstra, A. Nord, S. Carson, J. Wood, and T.D. Coates Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload Am. J. Hematol. 89 2013 391 394
30. N. Zhao, J. Gao, C.A. Enns, and M.D. Knutson ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin J. Biol. Chem. 285 2010 32141 32150
31. Y.Q. Li, B. Bai, Q.Q. Zheng, H. Yan, and G.H. Zhuang Quantitative study of iron metabolism-related genes expression in rat Biomed. Environ. Sci. 26 2013 808 819
32. M. Chloupkova, A.S. Zhang, and C.A. Enns Stoichiometries of transferrin receptors 1 and 2 in human liver Blood Cells Mol. Dis. 44 2010 28 33
33. D.M. Frazer, and G.J. Anderson The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol. Dis. 30 2003 288 297
34. A. Roetto, F. Daraio, F. Alberti, P. Porporato, A. Cali, M. De Gobbi, and C. Camaschella Hemochromatosis due to mutations in transferrin receptor 2 Blood Cells Mol. Dis. 29 2002 465 470
35. X. Tong, H. Kawabata, and H.P. Koeffler Iron deficiency can upregulate expression of transferrin receptor at both the mRNA and protein level Br. J. Haematol. 116 2002 458 464
36. T. Ganz, and E. Nemeth Iron metabolism: interactions with normal and disordered erythropoiesis Cold Spring Harbor Perspect. Med. 2 2012 a011668
37. A. Donovan, C.A. Lima, J.L. Pinkus, G.S. Pinkus, L.I. Zon, S. Robine, and N.C. Andrews The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis Cell Metab. 1 2005 191 200
38. L. Cianetti, M. Gabbianelli, and N.M. Sposi Ferroportin and erythroid cells: an update Adv. Hematol 2010 2010 404173
39. Z.M. Qian, Y.Z. Chang, G. Leung, J.R. Du, L. Zhu, Q. Wang, L. Niu, Y.J. Xu, L. Yang, K.P. Ho, and Y. Ke Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart Biochim. Biophys. Acta 1772 2007 527 532
40. L. Cianetti, P. Segnalini, A. Calzolari, O. Morsilli, F. Felicetti, C. Ramoni, M. Gabbianelli, U. Testa, and N.M. Sposi Expression of alternative transcripts of ferroportin-1 during human erythroid differentiation Haematologica 90 2005 1595 1606
41. E.W. Thackeray, S.O. Sanderson, J.C. Fox, and N. Kumar Hepatic iron overload or cirrhosis may occur in acquired copper deficiency and is likely mediated by hypoceruloplasminemia J. Clin. Gastroenterol. 45 2011 153 158
42. J.D. Huff, Y.K. Keung, M. Thakuri, M.W. Beaty, D.D. Hurd, J. Owen, and I. Molnar Copper deficiency causes reversible myelodysplasia Am. J. Hematol. 82 2007 625 630
43. X.T. Gregg, V. Reddy, and J.T. Prchal Copper deficiency masquerading as myelodysplastic syndrome Blood 100 2002 1493 1495
44. B. Qiao, P. Sugianto, E. Fung, A. Del-Castillo-Rueda, M.J. Moran-Jimenez, T. Ganz, and E. Nemeth Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination Cell Metab. 15 2012 918 924
45. E. Nemeth Hepcidin biology and therapeutic applications Expert Rev. Hematol. 3 2010 153 155
46. T. Ganz Hepcidin and iron regulation, 10 years later Blood 117 2011 4425 4433
47. C. Besson-Fournier, C. Latour, L. Kautz, J. Bertrand, T. Ganz, M.P. Roth, and H. Coppin Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling Blood 120 2012 431 439
48. E. Nemeth, E.V. Valore, M. Territo, G. Schiller, A. Lichtenstein, and T. Ganz Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein Blood 101 2003 2461 2463
49. N. Zhao, A.S. Zhang, and C.A. Enns Iron regulation by hepcidin J. Clin. Invest. 123 2013 2337 2343
50. M.W. Hentze, M.U. Muckenthaler, B. Galy, and C. Camaschella Two to tango: regulation of mammalian iron metabolism Cell 142 2010 24 38
51. K.E. Finberg, M.M. Heeney, D.R. Campagna, Y. Aydinok, H.A. Pearson, K.R. Hartman, M.M. Mayo, S.M. Samuel, J.J. Strouse, K. Markianos, N.C. Andrews, and M.D. Fleming Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA) Nat. Genet. 40 2008 569 571
52. S. Rivella The role of ineffective erythropoiesis in non-transfusion- dependent thalassemia Blood Rev. 26 Suppl. 1 2012 S12 S15
53. I.V. Libani, E.C. Guy, L. Melchiori, R. Schiro, P. Ramos, L. Breda, T. Scholzen, A. Chadburn, Y. Liu, M. Kernbach, B. Baron-Luhr, M. Porotto, M. de Sousa, E.A. Rachmilewitz, J.D. Hood, M.D. Cappellini, P.J. Giardina, R.W. Grady, J. Gerdes, and S. Rivella Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia Blood 112 2008 875 885
54. S.R. Pasricha, D.M. Frazer, D.K. Bowden, and G.J. Anderson Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study Blood 122 2013 124 133
55. A. Piperno, S. Galimberti, R. Mariani, S. Pelucchi, G. Ravasi, C. Lombardi, G. Bilo, M. Revera, A. Giuliano, A. Faini, V. Mainini, M. Westerman, T. Ganz, M.G. Valsecchi, G. Mancia, and G. Parati HIGHCARE investigators. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project Blood 117 2011 2953 2959
56. T. Tanno, N.V. Bhanu, P.A. Oneal, S.H. Goh, P. Staker, Y.T. Lee, J.W. Moroney, C.H. Reed, N.L. Luban, R.H. Wang, T.E. Eling, R. Childs, T. Ganz, S.F. Leitman, S. Fucharoen, and J.L. Miller High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat. Med. 13 2007 1096 1101
57. S. Gardenghi, M.F. Marongiu, P. Ramos, E. Guy, L. Breda, A. Chadburn, Y. Liu, N. Amariglio, G. Rechavi, E.A. Rachmilewitz, W. Breuer, Z.I. Cabantchik, D.M. Wrighting, N.C. Andrews, M. de Sousa, P.J. Giardina, R.W. Grady, and S. Rivella Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin Blood 109 2007 5027 5035
58. A. Piperno, R. Mariani, P. Trombini, and D. Girelli Hepcidin modulation in human diseases: from research to clinic World J. Gastroenterol. 15 2009 538 551
59. T. Tanno, and J.L. Miller Iron loading and overloading due to ineffective erythropoiesis Adv. Hematol 2010 2010 358283
60. L. Silvestri, A. Pagani, and C. Camaschella Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis Blood 111 2008 924 931
61. L. Kautz, G. Jung, E. Nemeth, and T. Ganz The erythroid factor erythroferrone and its role in iron homeostasis Blood 122 21 2013
62. O. Loreal, I. Gosriwatana, D. Guyader, J. Porter, P. Brissot, and R.C. Hider Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method J. Hepatol. 32 2000 727 733
63. L. Sahlstedt, F. Ebeling, L. von Bonsdorff, J. Parkkinen, and T. Ruutu Non-transferrin-bound iron during allogeneic stem cell transplantation Br. J. Haematol. 113 2001 836 838
64. S.J. Bradley, I. Gosriwitana, S. Srichairatanakool, R.C. Hider, and J.B. Porter Non-transferrin-bound iron induced by myeloablative chemotherapy Br. J. Haematol. 99 1997 337 343
65. J.M. Roob, G. Khoschsorur, A. Tiran, J.H. Horina, H. Holzer, and B.M. Winklhofer-Roob Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis J. Am. Soc. Nephrol. 11 2000 539 549
66. Z.I. Cabantchik, Y.S. Sohn, W. Breuer, and B.P. Esposito The molecular and cellular basis of iron toxicity in iron overload disorders: diagnostic and therapeutic approaches Thalassemia Rep. 3 2013 7 13
67. B.P. Esposito, W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko, and Z.I. Cabantchik Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 102 2003 2670 2677
68. R.C. Hider, and X.L. Kong Glutathione: a key component of the cytoplasmic labile iron pool Biometals 24 2011 1179 1187
69. M.B. Troadec, D. Warner, J. Wallace, K. Thomas, G.J. Spangrude, J. Phillips, O. Khalimonchuk, B.H. Paw, D.M. Ward, and J. Kaplan Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria Blood 117 2011 5494 5502
70. R.A. Fawwaz, H.S. Winchell, M. Pollycove, and T. Sargent Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity Blood 30 1967 417 424
71. P. Brissot, G. Zanninelli, D. Guyader, J. Zeind, and J. Gollan Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders Am. J. Physiol. 267 1994 G135 G142
72. H. Gunshin, Y. Fujiwara, A.O. Custodio, C. Direnzo, S. Robine, and N.C. Andrews Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver J. Clin. Invest. 115 2005 1258 1266
73. J.P. Liuzzi, F. Aydemir, H. Nam, M.D. Knutson, and R.J. Cousins Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells Proc. Natl. Acad. Sci. USA 103 2006 13612 13617
74. V. Berdoukas, A. Nord, S. Carson, M. Puliyel, T. Hofstra, J. Wood, and T.D. Coates Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age Am. J. Hematol. 88 2013 E283 E285
75. A.S. Zhang, S. Xiong, H. Tsukamoto, and C.A. Enns Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes Blood 103 2004 1509 1514
76. P. Brissot, M. Ropert, C. Le Lan, and O. Loreal Non-transferrin bound iron: a key role in iron overload and iron toxicity Biochim. Biophys. Acta 1820 2012 403 410
77. 2+ channel modifiers: possible implications in iron overload Circ. Res. 84 1999 1302 1309
78. G. Ramey, J.C. Deschemin, B. Durel, F. Canonne-Hergaux, G. Nicolas, and S. Vaulont Hepcidin targets ferroportin for degradation in hepatocytes Haematologica 95 2010 501 504
79. R. Hultcrantz, B. Angelin, E. Bjorn-Rasmussen, S. Ewerth, and K. Einarsson Biliary excretion of iron and ferritin in idiopathic hemochromatosis Gastroenterology 96 1989 1539 1545
80. M.I. Cleton, J.W. Sindram, L.H. Rademakers, F.M. Zuyderhoudt, W.C. De Bruijn, and J.J. Marx Ultrastructural evidence for the presence of ferritin-iron in the biliary system of patients with iron overload Hepatology 6 1986 30 35
81. R. Raedsch, A. Stiehl, S. Walker, L. Theilmann, B. Kommerell, R. Waldherr, and M. Senn Biliary excretion of iron in healthy man and in patients with alcoholic cirrhosis of the liver Clin. Chim. Acta 193 1990 49 54
82. P. Brissot, U. Bolder, C.D. Schteingart, J. Arnaud, and A.F. Hofmann Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats Hepatology 25 1997 1457 1461
83. R.W. Grady, R. Galanello, R.E. Randolph, D.A. Kleinert, C. Dessi, and P.J. Giardina Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine Haematologica 98 2013 129 135
84. R. Galanello, A. Agus, S. Campus, F. Danjou, P.J. Giardina, and R.W. Grady Combined iron chelation therapy Ann. N. Y. Acad. Sci. 1202 2010 79 86
85. J.G. Parkes, E.W. Randell, N.F. Olivieri, and D.M. Templeton Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells Biochim. Biophys. Acta 1243 1995 373 380
86. E.W. Randell, J.G. Parkes, N.F. Olivieri, and D.M. Templeton Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron J. Biol. Chem. 269 1994 16046 16053
87. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy Nat. Med. 9 2003 1187 1194
88. + channels Eur. J. Haematol. 88 2012 476 477
89. S. Kumfu, S. Chattipakorn, K. Chinda, S. Fucharoen, and N. Chattipakorn T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice Eur. J. Haematol. 88 2012 535 548
90. S. Kumfu, S. Chattipakorn, S. Srichairatanakool, J. Settakorn, S. Fucharoen, and N. Chattipakorn T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice Eur. J. Haematol. 86 2011 156 166
91. M. Schranzhofer, M. Schifrer, J.A. Cabrera, S. Kopp, P. Chiba, H. Beug, and E.W. Mullner Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis Blood 107 2006 4159 4167
92. J. Ahn, and R.M. Johnstone Origin of a soluble truncated transferrin receptor Blood 81 1993 2442 2451
93. G. Karthikeyan, L.K. Lewis, and M.A. Resnick The mitochondrial protein frataxin prevents nuclear damage Hum. Mol. Genet. 11 2002 1351 1362
94. S. Rivella Ineffective erythropoiesis and thalassemias Curr. Opin. Hematol. 16 2009 187 194
95. H. Li, A.C. Rybicki, S.M. Suzuka, L. von Bonsdorff, W. Breuer, C.B. Hall, Z.I. Cabantchik, E.E. Bouhassira, M.E. Fabry, and Y.Z. Ginzburg Transferrin therapy ameliorates disease in beta-thalassemic mice Nat. Med. 16 2010 177 182
96. T. Tanno, P. Porayette, O. Sripichai, S.J. Noh, C. Byrnes, A. Bhupatiraju, Y.T. Lee, J.B. Goodnough, O. Harandi, T. Ganz, R.F. Paulson, and J.L. Miller Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells Blood 114 2009 181 186
97. S. Gardenghi, P. Ramos, M.F. Marongiu, L. Melchiori, L. Breda, E. Guy, K. Muirhead, N. Rao, C.N. Roy, N.C. Andrews, E. Nemeth, A. Follenzi, X. An, N. Mohandas, Y. Ginzburg, E.A. Rachmilewitz, P.J. Giardina, R.W. Grady, and S. Rivella Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice J. Clin. Invest. 120 2010 4466 4477
98. G.C. Preza, P. Ruchala, R. Pinon, E. Ramos, B. Qiao, M.A. Peralta, S. Sharma, A. Waring, T. Ganz, and E. Nemeth Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload J. Clin. Invest. 121 2011 4880 4888
99. S. Guo, C. Casu, S. Gardenghi, S. Booten, M. Aghajan, R. Peralta, A. Watt, S. Freier, B.P. Monia, and S. Rivella Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice J. Clin. Invest. 123 2013 1531 1541
100. -/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia Blood 121 2013 1200 1208
101. M.D. Cappellini, J. Porter, R. Origa, G.L. Forni, A. Laadem, F. Galacteros, D. Miteva, V. Sung, R. Chopra, J.-B. Arlet, J.-A. Ribeil, K. Klesczewski, K. Attie, M. Garbowski, and O. Hermine A phase 2a, open-label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)-thalassemia: interim results Blood 122 2013 3448
102. S. Fucharoen, and D.J. Weatherall The hemoglobin E thalassemias Cold Spring Harbor Perspect. Med. 2 2012 a011734
103. D.R. Higgs, J.D. Engel, and G. Stamatoyannopoulos Thalassaemia Lancet 379 2012 373 383
104. A.W. Nienhuis, and D.G. Nathan Pathophysiology and clinical manifestations of the beta-thalassemias Cold Spring Harbor Perspect. Med. 2 2012 a011726
105. N. Gattermann Pathophysiological and clinical aspects of iron chelation therapy in MDS Curr. Pharm. Des. 18 2012 3222 3234
106. A. Dong, S. Rivella, and L. Breda Gene therapy for hemoglobinopathies: progress and challenges Transl. Res. 161 2013 293 306
107. H.A. Dailey, and P.N. Meissner Erythroid heme biosynthesis and its disorders Cold Spring Harbor Perspect. Med. 3 2013 a011676
108. M.D. Fleming Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation Hematol. Am. Soc. Hematol. Educ. Program 2011 2011 525 531
109. A. Iolascon, R. Russo, and J. Delaunay Congenital dyserythropoietic anemias Curr. Opin. Hematol. 18 2011 146 151
110. D.R. Powars, L.S. Chan, A. Hiti, E. Ramicone, and C. Johnson Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients Medicine (Baltimore) 84 2005 363 376
111. C.T. Quinn, Z.R. Rogers, T.L. McCavit, and G.R. Buchanan Improved survival of children and adolescents with sickle cell disease Blood 115 2010 3447 3452
112. J. Makani, S.E. Cox, D. Soka, A.N. Komba, J. Oruo, H. Mwamtemi, P. Magesa, S. Rwezaula, E. Meda, J. Mgaya, B. Lowe, D. Muturi, D.J. Roberts, T.N. Williams, K. Pallangyo, J. Kitundu, G. Fegan, F.J. Kirkham, K. Marsh, and C.R. Newton Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania PLoS One 6 2011 e14699
113. Y. Saunthararajah, and E. Vichinsky Sickle cell disease: clinical features and management R. Hoffman, B. Furie, E.J. Benz, P. McGlave, L.E. Silberstein, S.J. Shattil, Hematology: Basic Principles and Practice 2008 Churchill Livingstone Philadelphia
114. J.M. Lipton, and S.R. Ellis Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis Hematol. Oncol. Clin. North Am. 23 2009 261 282
115. A. Vlachos, S. Ball, N. Dahl, B.P. Alter, S. Sheth, U. Ramenghi, J. Meerpohl, S. Karlsson, J.M. Liu, T. Leblanc, C. Paley, E.M. Kang, E.J. Leder, E. Atsidaftos, A. Shimamura, M. Bessler, B. Glader, and J.M. Lipton Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference Br. J. Haematol. 142 2008 859 876
116. N. Gattermann, and E.A. Rachmilewitz Iron overload in MDS - pathophysiology, diagnosis, and complications Ann. Hematol. 90 2011 1 10
117. J.E. Nelson, V.R. Mugford, E. Kilcourse, R.S. Wang, and K.V. Kowdley Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects Am. J. Physiol. Gastrointest. Liver Physiol. 298 2010 G57 G62
118. A. Pietrangelo Hereditary hemochromatosis - a new look at an old disease N. Engl. J. Med. 350 2004 2383 2397
119. C. Camaschella Iron and hepcidin: a story of recycling and balance Hematol. Am. Soc. Hematol. Educ. Program 2013 2013 1 8
120. C. Camaschella How I manage patients with atypical microcytic anaemia Br. J. Haematol. 160 2013 12 24
121. R.E. Fleming, and P. Ponka Iron overload in human disease N. Engl. J. Med. 366 2012 348 359
122. A. Pietrangelo Hepcidin in human iron disorders: therapeutic implications J. Hepatol. 54 2011 173 181
123. J.B. Porter Practical management of iron overload Br. J. Haematol. 115 2001 239 252
124. A. Piga, F. Longo, L. Duca, S. Roggero, T. Vinciguerra, R. Calabrese, C. Hershko, and M.D. Cappellini High nontransferrin bound iron levels and heart disease in thalassemia major Am. J. Hematol. 84 2009 29 33
125. S. Fargion, M.T. Taddei, V. Gabutti, A. Piga, A. Di Palma, L. Capra, G. Fontanelli, and A. Avanzini Early iron overload in beta-thalassaemia major: when to start chelation therapy? Arch. Dis. Child. 57 1982 929 933
126. P.J. Giardina, and B.G. Forget Thalassemia syndromes R. Hoffman, B. Furie, E.J. Benz, P. McGlave, L.E. Silberstein, S.J. Shattil, Hematology: Basic Principles and Practice 2008 Churchill Livingstone Philadelphia 535 562
127. N.F. Olivieri, D.G. Nathan, J.H. MacMillan, A.S. Wayne, P.P. Liu, A. McGee, M. Martin, G. Koren, and A.R. Cohen Survival in medically treated patients with homozygous beta-thalassemia N. Engl. J. Med. 331 1994 574 578
128. E. Angelucci, G.M. Brittenham, C.E. McLaren, M. Ripalti, D. Baronciani, C. Giardini, M. Galimberti, P. Polchi, and G. Lucarelli Hepatic iron concentration and total body iron stores in thalassemia major N. Engl. J. Med. 343 2000 327 331
129. G.M. Brittenham, A.R. Cohen, C.E. McLaren, M.B. Martin, P.M. Griffith, A.W. Nienhuis, N.S. Young, C.J. Allen, D.E. Farrell, and J.W. Harris Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major Am. J. Hematol. 42 1993 81 85
130. J.C. Wood, C. Enriquez, N. Ghugre, J.M. Tyzka, S. Carson, M.D. Nelson, and T.D. Coates MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients Blood 106 2005 1460 1465
131. J.C. Wood, J.M. Tyszka, S. Carson, M.D. Nelson, and T.D. Coates Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease Blood 103 2004 1934 1936
132. T.G. St Pierre, P.R. Clark, W. Chua-anusorn, A.J. Fleming, G.P. Jeffrey, J.K. Olynyk, P. Pootrakul, E. Robins, and R. Lindeman Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance Blood 105 2005 855 861
133. L.J. Noetzli, J. Papudesi, T.D. Coates, and J.C. Wood Pancreatic iron loading predicts cardiac iron loading in thalassemia major Blood 114 2009 4021 4026
134. L.J. Noetzli, A. Panigrahy, M. Joukar, A. Hyderi, S.D. Mittelman, T. Coates, and J.C. Wood Pituitary iron and volume in transfusional iron overload Blood (ASH Annual Meeting Abstracts) 114 2009 2017 ([Abstract])
135. C.J. Brewer, T.D. Coates, and J.C. Wood Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major J. Magn. Reson. Imaging 29 2009 357 364
136. L.J. Noetzli, T.D. Coates, S.D. Mittelman, and J.C. Wood Pancreatic iron and pancreatic function in thalassemia Blood (ASH Annual Meeting Abstracts) 112 2008 3876 ([Abstract])
137. L.J. Anderson, S. Holden, B. Davis, E. Prescott, C.C. Charrier, N.H. Bunce, D.N. Firmin, B. Wonke, J. Porter, J.M. Walker, and D.J. Pennell Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload Eur. Heart J. 22 2001 2171 2179
138. P. Kirk, M. Roughton, J.B. Porter, J.M. Walker, M.A. Tanner, J. Patel, D. Wu, J. Taylor, M.A. Westwood, L.J. Anderson, and D.J. Pennell Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major Circulation 120 2009 1961 1968
139. L.J. Noetzli, A. Panigrahy, A. Hyderi, A. Dongelyan, T.D. Coates, and J.C. Wood Pituitary iron and volume imaging in healthy controls Am. J. Neuroradiol. 33 2012 259 265
140. L.J. Noetzli, A. Panigrahy, S.D. Mittelman, A. Hyderi, A. Dongelyan, T.D. Coates, and J.C. Wood Pituitary iron and volume predict hypogonadism in transfusional iron overload Am. J. Hematol. 87 2012 167 171
141. L.J. Noetzli, S.D. Mittelman, R.M. Watanabe, T.D. Coates, and J.C. Wood Pancreatic iron and glucose dysregulation in thalassemia major Am. J. Hematol. 87 2012 155 160
142. J.C. Wood Impact of iron assessment by MRI Hematol. Am. Soc. Hematol. Educ. Program 2011 2011 443 450
143. J.P. Carpenter, T. He, P. Kirk, M. Roughton, L.J. Anderson, S.V. de Noronha, M.N. Sheppard, J.B. Porter, J.M. Walker, J.C. Wood, R. Galanello, G. Forni, G. Catani, G. Matta, S. Fucharoen, A. Fleming, M.J. House, G. Black, D.N. Firmin, T.G. St Pierre, and D.J. Pennell On T2* magnetic resonance and cardiac iron Circulation 123 2011 1519 1528
144. J.C. Wood, M. Otto-Duessel, M. Aguilar, H. Nick, M.D. Nelson, T.D. Coates, H. Pollack, and R. Moats Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy Circulation 112 2005 535 543
145. N.R. Ghugre, and J.C. Wood Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model Magn. Reson. Med. 65 2011 837 847
146. G. Crisponi, R. Ambu, F. Cristiani, G. Mancosu, V.M. Nurchi, R. Pinna, and G. Faa Does iron concentration in a liver needle biopsy accurately reflect hepatic iron burden in beta-thalassemia? Clin. Chem. 46 2000 1185 1188
147. J.S. Cheung, W.Y. Au, S.Y. Ha, D. Kim, J.H. Jensen, I.Y. Zhou, M.M. Cheung, Y. Wu, H. Guo, P.L. Khong, T.R. Brown, G.M. Brittenham, and E.X. Wu Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia J. Magn. Reson. Imaging 33 2011 1510 1516
148. L.J. Noetzli, T.D. Coates, and J.C. Wood Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major Br. J. Haematol. 152 2011 229 233
149. L.J. Anderson, M.A. Westwood, S. Holden, B. Davis, E. Prescott, B. Wonke, J.B. Porter, J.M. Walker, and D.J. Pennell Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance Br. J. Haematol. 127 2004 348 355
150. C.M. Craven, J. Alexander, M. Eldridge, J.P. Kushner, S. Bernstein, and J. Kaplan Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis Proc. Natl. Acad. Sci. USA 84 1987 3457 3461
151. T.C. Iancu, R.J. Ward, and T.J. Peters Ultrastructural observations in the carbonyl iron-fed rat, an animal model for hemochromatosis Virchows Arch. B 53 1987 208 217
152. J.C. Wood, R. Origa, A. Agus, G. Matta, T.D. Coates, and R. Galanello Onset of cardiac iron loading in pediatric patients with thalassemia major Haematologica 93 2008 917 920
153. A. Koren, D. Fink, O. Admoni, Y. Tennenbaum-Rakover, and C. Levin Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients Eur. J. Haematol. 84 2010 72 78
154. P.B. Walter, E.B. Fung, D.W. Killilea, Q. Jiang, M. Hudes, J. Madden, J. Porter, P. Evans, E. Vichinsky, and P. Harmatz Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease Br. J. Haematol. 135 2006 254 263
155. J.J. Kroot, C.M. Laarakkers, E.H. Kemna, B.J. Biemond, and D.W. Swinkels Regulation of serum hepcidin levels in sickle cell disease Haematologica 94 2009 885 887
156. D.J. Pennell, J.B. Porter, A. Piga, Y. Lai, A. El-Beshlawy, K.M. Belhoul, M. Elalfy, A. Yesilipek, Y. Kilinc, T. Lawniczek, D. Habr, M. Weisskopf, Y. Zhang, and Y. Aydinok A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA) Blood 123 2014 1447 1454
157. J.C. Wood, B.P. Kang, A. Thompson, P. Giardina, P. Harmatz, T. Glynos, C. Paley, and T.D. Coates The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores Blood 116 2010 537 543
158. K. Farmaki, I. Tzoumari, C. Pappa, G. Chouliaras, and V. Berdoukas Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major Br. J. Haematol. 148 2010 466 475
159. E. Vichinsky, E. Butensky, E. Fung, M. Hudes, E. Theil, L. Ferrell, R. Williams, L. Louie, P.D. Lee, and P. Harmatz Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia Am. J. Hematol. 80 2005 70 74
160. A. El Beshlawy, I. Alaraby, M.S. Abdel Kader, D.H. Ahmed, and H.E. Abdelrahman Study of serum hepcidin in hereditary hemolytic anemias Hemoglobin 36 2012 555 570
161. S.L. Kearney, E. Nemeth, E.J. Neufeld, D. Thapa, T. Ganz, D.A. Weinstein, and M.J. Cunningham Urinary hepcidin in congenital chronic anemias Pediatr. Blood Cancer 48 2007 57 63
162. P. Ramos, E. Guy, N. Chen, C.C. Proenca, S. Gardenghi, C. Casu, A. Follenzi, N. Van Rooijen, R.W. Grady, M. de Sousa, and S. Rivella Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis Blood 117 2011 1379 1389
163. M. Andreani, F.C. Radio, M. Testi, C. De Bernardo, M. Troiano, S. Majore, P. Bertucci, P. Polchi, R. Rosati, and P. Grammatico Association of hepcidin promoter c.-582 A>G variant and iron overload in thalassemia major Haematologica 94 2009 1293 1296
164. R. Miniero, I. Tardivo, A. Roetto, and M. De Gobbi Heterozygous
165. A. Riva, R. Mariani, G. Bovo, S. Pelucchi, C. Arosio, A. Salvioni, A. Vergani, and A. Piperno Type 3 hemochromatosis and beta-thalassemia trait Eur. J. Haematol. 72 2004 370 374
166. M. De Gobbi, P. Pasquero, F. Brunello, P. Paccotti, U. Mazza, and C. Camaschella Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin Haematologica 85 2000 865 867
167. V.R. Arruda, M.F. Agostinho, R. Cancado, F.F. Costa, and S.T.O. Saad beta-Thalassemia trait might increase the severity of hemochromatosis in subjects with the C282Y mutation in the HFE gene Am. J. Hematol. 63 2000 (230-230)
168. M. Benkerrou, C. Alberti, N. Couque, Z. Haouari, A. Ba, F. Missud, P. Boizeau, L. Holvoet, G. Ithier, J. Elion, A. Baruchel, and R. Ducrocq Impact of glucose-6-phosphate dehydrogenase deficiency on sickle cell anaemia expression in infancy and early childhood: a prospective study Br. J. Haematol. 163 2013 646 654
169. A. Pamba, N.D. Richardson, N. Carter, S. Duparc, Z. Premji, A.B. Tiono, and L. Luzzatto Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone Blood 120 2012 4123 4133
170. H.A. Al-Nood Thalassaemia and glucose-6-phosphate dehydrogenase deficiency in sickle-cell disorder patients in Taiz, Yemen East. Mediterr. Health J. 17 2011 404 408
171. M. Nouraie, N.S. Reading, A. Campbell, C.P. Minniti, S.R. Rana, L. Luchtman-Jones, G.J. Kato, M.T. Gladwin, O.L. Castro, J.T. Prchal, and V.R. Gordeuk Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia Br. J. Haematol. 150 2010 218 225
172. F. Bernaudin, S. Verlhac, S. Chevret, M. Torres, L. Coic, C. Arnaud, A. Kamdem, I. Hau, M.G. Neonato, and C. Delacourt G6PD deficiency, absence of alpha-thalassemia and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia Blood 112 2008 4314 4317
173. G. Vinci, S. Christin-Maitre, M. Pasquier, P. Bouchard, M. Fellous, and R.A. Veitia FOXO3a variants in patients with premature ovarian failure Clin. Endocrinol. 68 2008 495 497
174. B. Wang, Y. Mu, F. Ni, S. Zhou, J. Wang, Y. Cao, and X. Ma Analysis of FOXO3 mutation in 114 Chinese women with premature ovarian failure Reprod. Biomed. Online 20 2010 499 503
175. M. Ibarrola-Villava, M. Pena-Chilet, L.P. Fernandez, J.A. Aviles, M. Mayor, M. Martin-Gonzalez, C. Gomez-Fernandez, B. Casado, P. Lazaro, A. Lluch, J. Benitez, R. Lozoya, E. Boldo, A. Pizarro, C. Martinez-Cadenas, and G. Ribas Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility Eur. J. Cancer 47 2011 2618 2625
176. S. Silva-Gomes, A.G. Santos, C. Caldas, C.M. Silva, J.V. Neves, J. Lopes, F. Carneiro, P.N. Rodrigues, and T.L. Duarte Transcription factor NRF2 protects mice against dietary iron-induced liver injury by preventing hepatocytic cell death J. Hepatol. 60 2014 354 361
177. S. Santos Franco, L. De Falco, S. Ghaffari, C. Brugnara, D.A. Sinclair, A. Matte, A. Iolascon, N. Mohandas, M. Bertoldi, X. An, A. Siciliano, P. Rimmele, M.D. Cappellini, S. Michan, E. Zoratti, A. Janin, and L. De Franceschi Resveratrol accelerates erythroid maturation by activation of FOXO3 and ameliorates anemia in beta-thalassemic mice Haematologica 99 2 2014 267 275
178. S. Ghaffari Oxidative stress in the regulation of normal and neoplastic hematopoiesis Antioxid. Redox Signaling 10 2008 1923 1940
179. D. Marinkovic, X. Zhang, S. Yalcin, J.P. Luciano, C. Brugnara, T. Huber, and S. Ghaffari Foxo3 is required for the regulation of oxidative stress in erythropoiesis J. Clin. Invest. 117 2007 2133 2144
180. S.J. Dixon, and B.R. Stockwell The role of iron and reactive oxygen species in cell death Nat. Chem. Biol. 10 2013 9 17
181. F. Longo, G. Zecchina, L. Sbaiz, R. Fischer, A. Piga, and C. Camaschella The influence of hemochromatosis mutations on iron overload of thalassemia major Haematologica 84 1999 799 803
182. E. Poggiali, F. Andreozzi, I. Nava, P. Delbini, L. Duca, S. Forti, G. Graziadei, A. Marcon, and M.D. Domenica Cappellini Analysis of TMPRSS6 polymorphisms in patients with iron deficiency anemia partially responsive to oral iron treatment Blood 122 2013 3438
183. T.E. Galesloot, A.J. Geurts-Moespot, M. den Heijer, F.C. Sweep, R.E. Fleming, L.A. Kiemeney, S.H. Vermeulen, and D.W. Swinkels Associations of common variants in HFE and TMPRSS6 with iron parameters are independent of serum hepcidin in a general population: a replication study J. Med. Genet. 50 2013 593 598
184. S. Pelusi, D. Girelli, R. Rametta, N. Campostrini, C. Alfieri, M. Traglia, P. Dongiovanni, G. Como, D. Toniolo, C. Camaschella, P. Messa, S. Fargion, and L. Valenti The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis BMC Nephrol. 14 2013 48
185. S. Claster, J.C. Wood, L. Noetzli, S.M. Carson, T.C. Hofstra, R. Khanna, and T.D. Coates Nutritional deficiencies in iron overloaded patients with hemoglobinopathies Am. J. Hematol. 84 2009 344 348
186. N.A. McKeag, M.C. McKinley, J.V. Woodside, M.T. Harbinson, and P.P. McKeown The role of micronutrients in heart failure J. Acad. Nutr. Diet. 112 2012 870 886
187. M. Dimitriadou, A. Christoforidis, M. Economou, I. Tsatra, E. Vlachaki, L. Fidani, G. Katzos, and M. Athanassiou-Metaxa Elevated serum parathormone levels are associated with myocardial iron overload in patients with beta-thalassaemia major Eur. J. Haematol. 84 2010 64 71
188. J.C. Wood, S. Claster, S. Carson, J.D. Menteer, T. Hofstra, R. Khanna, and T. Coates Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major Br. J. Haematol. 141 2008 891 894
189. P.D. Jensen, F.T. Jensen, T. Christensen, J.L. Nielsen, and J. Ellegaard Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias Blood 101 2003 91 96
190. E. Angelucci, P. Muretto, A. Nicolucci, D. Baronciani, B. Erer, J. Gaziev, M. Ripalti, P. Sodani, S. Tomassoni, G. Visani, and G. Lucarelli Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation Blood 100 2002 17 21
191. J. Amer, Z. Etzion, R.M. Bookchin, and E. Fibach Oxidative status of valinomycin-resistant normal, beta-thalassemia and sickle red blood cells Biochim. Biophys. Acta 1760 2006 793 799
192. J. Amer, D. Atlas, and E. Fibach N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells Biochim. Biophys. Acta 1780 2008 249 255
193. E. Fibach, and E. Rachmilewitz The role of oxidative stress in hemolytic anemia Curr. Mol. Med. 8 2008 609 619
194. E. Fibach, and E.A. Rachmilewitz The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia Ann. N. Y. Acad. Sci. 1202 2010 10 16
195. E. Fibach, E. Prus, N. Bianchi, C. Zuccato, G. Breveglieri, F. Salvatori, A. Finotti, M. Lipucci di Paola, E. Brognara, I. Lampronti, M. Borgatti, and R. Gambari Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and beta-thalassemia patients Int. J. Mol. Med. 29 2012 974 982
196. O. Castro, and T.B. Haddy Improved survival of iron-deficient patients with sickle erythrocytes N. Engl. J. Med. 308 1983 527
197. O. Castro, W.N. Poillon, H. Finke, and E. Massac Improvement of sickle cell anemia by iron-limited erythropoiesis Am. J. Hematol. 47 1994 74 81
198. L. De Franceschi, M. Bertoldi, A. Matte, S. Santos Franco, A. Pantaleo, E. Ferru, and F. Turrini Oxidative stress and beta-thalassemic erythroid cells behind the molecular defect Oxid. Med. Cell. Longevity 2013 2013 985210
199. L. de Franceschi, O. Shalev, A. Piga, M. Collell, O. Olivieri, R. Corrocher, R.P. Hebbel, and C. Brugnara Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity J. Lab. Clin. Med. 133 1999 64 69
200. P.V. Browne, O. Shalev, F.A. Kuypers, C. Brugnara, A. Solovey, N. Mohandas, S.L. Schrier, and R.P. Hebbel Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia J. Clin. Invest. 100 1997 1459 1464
201. O. Olivieri, L. De Franceschi, M.D. Capellini, D. Girelli, R. Corrocher, and C. Brugnara Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias Blood 84 1994 315 320
202. P.D. Jensen Iron overload in patients with myelodysplastic syndromes Curr. Hematol. Malig. Rep 2 2007 13 21
203. P.D. Jensen, L. Heickendorff, B. Pedersen, K. Bendix-Hansen, F.T. Jensen, T. Christensen, A.M. Boesen, and J. Ellegaard The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br. J. Haematol. 94 1996 288 299
204. R. Guariglia, M.C. Martorelli, O. Villani, G. Pietrantuono, G. Mansueto, F. D'Auria, V. Grieco, G. Bianchino, R. Lerose, G.B. Bochicchio, and P. Musto Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review Leuk. Res. 35 2011 566 570
205. H. Ghoti, E. Fibach, M. Westerman, O. Gordana, T. Ganz, and E.A. Rachmilewitz Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome Br. J. Haematol. 153 2011 118 120
206. E.N. Oliva, F. Ronco, A. Marino, C. Alati, G. Pratico, and F. Nobile Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients Transfusion 50 2010 1568 1570
207. M.A. Badawi, L.M. Vickars, J.M. Chase, and H.A. Leitch Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome Adv. Hematol. 2010 2010 164045
208. E. Messa, D. Cilloni, F. Messa, F. Arruga, A. Roetto, and G. Saglio Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis Acta Haematol. 120 2008 70 74
209. N. Gattermann, C. Finelli, M. Della Porta, P. Fenaux, M. Stadler, A. Guerci-Bresler, M. Schmid, K. Taylor, D. Vassilieff, D. Habr, A. Marcellari, B. Roubert, and C. Rose Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes Haematologica 97 2012 1364 1371
210. J.W. Lee, P.S. Jang, N.G. Chung, B. Cho, D.C. Jeong, and H.K. Kim Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia Pediatr. Hematol. Oncol. 28 2011 718 720
211. K.N. Koh, M. Park, B.E. Kim, H.J. Im, and J.J. Seo Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia J. Pediatr. Hematol. Oncol. 32 2010 611 614
212. A.K. Bergmann, H. Tamary, and E.J. Neufeld Remission from transfusion-dependence in a patient with congenital dyserythropoietic anemia (CDA) and increased intensity of iron chelation Pediatr. Blood Cancer 53 2009 1167 1168
213. W. Lu, M. Zhao, S. Rajbhandary, F. Xie, X. Chai, J. Mu, J. Meng, Y. Liu, Y. Jiang, X. Xu, and A. Meng Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients Eur. J. Haematol. 91 2013 249 261
214. K. Taoka, K. Kumano, F. Nakamura, M. Hosoi, S. Goyama, Y. Imai, A. Hangaishi, and M. Kurokawa The effect of iron overload and chelation on erythroid differentiation Int. J. Hematol. 95 2012 149 159
215. S. Kikuchi, M. Kobune, S. Iyama, T. Sato, K. Murase, Y. Kawano, K. Takada, K. Ono, Y. Kaneko, K. Miyanishi, Y. Sato, T. Hayashi, R. Takimoto, and J. Kato Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox Free Radic. Biol. Med. 53 2012 643 648
216. M. Schmid Iron chelation therapy in MDS: what have we learnt recently? Blood Rev. 23 Suppl. 1 2009 S21 S25
217. T.S. Koskenkorva-Frank, G. Weiss, W.H. Koppenol, and S. Burckhardt The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress Free Radic. Biol. Med. 65 2013 1174 1194
218. K.C. Wood, L.L. Hsu, and M.T. Gladwin Sickle cell disease vasculopathy: a state of nitric oxide resistance Free Radic. Biol. Med. 44 2008 1506 1528
219. J.B. Porter, R.D. Abeysinghe, L. Marshall, R.C. Hider, and S. Singh Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 1996 705 713
220. Z.I. Cabantchik, W. Breuer, G. Zanninelli, and P. Cianciulli LPI-labile plasma iron in iron overload Best Pract. Res. Clin. Haematol. 18 2005 277 287
221. B.A. Davis, and J.B. Porter Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia Blood 95 2000 1229 1236
222. J. Porter, R. Galanello, G. Saglio, E.J. Neufeld, E. Vichinsky, M.D. Cappellini, N. Olivieri, A. Piga, M.J. Cunningham, D. Soulieres, N. Gattermann, G. Tchernia, J. Maertens, P. Giardina, J. Kwiatkowski, G. Quarta, M. Jeng, G.L. Forni, M. Stadler, H. Cario, L. Debusscher, M. Della Porta, M. Cazzola, P. Greenberg, G. Alimena, B. Rabault, I. Gathmann, J.M. Ford, D. Alberti, and C. Rose Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study Eur. J. Haematol. 80 2008 168 176
223. V. Berdoukas, K. Farmaki, J.C. Wood, and T. Coates Iron chelation in thalassemia: time to reconsider our comfort zones Expert Rev. Hematol. 4 2011 17 26
224. E. Voskaridou, V. Komninaka, A. Karavas, E. Terpos, V. Akianidis, and D. Christoulas Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden Transfusion 54 2014 646 649
225. A. Piga, F. Longo, K.M. Musallam, M.D. Cappellini, G.L. Forni, G. Quarta, F. Chiavilli, F. Commendatore, S. Mulas, V. Caruso, and R. Galanello Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project Br. J. Haematol. 161 2013 872 883
226. A. Maggio, A. Vitrano, G. Lucania, M. Capra, L. Cuccia, F. Gagliardotto, L. Pitrolo, L. Prossomariti, A. Filosa, V. Caruso, C. Gerardi, S. Campisi, P. Cianciulli, M. Rizzo, G. D'Ascola, A. Ciancio, R. Di Maggio, G. Calvaruso, G.R. Pantalone, and P. Rigano Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients Am. J. Hematol. 87 2012 732 733
227. K. Farmaki, I. Tzoumari, and C. Pappa Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications Blood Cells Mol. Dis. 47 2011 33 40
228. Y. Beguin, M. Aapro, H. Ludwig, L. Mizzen, and A. Osterborg Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis - a critical review Crit. Rev. Oncol./Hematol. 89 2014 1 15
229. S.V. Torti, and F.M. Torti Iron and cancer: more ore to be mined Nat. Rev. Cancer 13 2013 342 355
230. C. Niederau, R. Fischer, A. Sonnenberg, W. Stremmel, H.J. Trampisch, and G. Strohmeyer Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis N. Engl. J. Med. 313 1985 1256 1262
231. C. Niederau, R. Fischer, A. Purschel, W. Stremmel, D. Haussinger, and G. Strohmeyer Long-term survival in patients with hereditary hemochromatosis Gastroenterology 110 1996 1107 1119
232. L.R. Zacharski, B.K. Chow, P.S. Howes, G. Shamayeva, J.A. Baron, R.L. Dalman, D.J. Malenka, C.K. Ozaki, and P.W. Lavori Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial J. Natl. Cancer Inst. 100 2008 996 1002
233. K.V. Iron Kowdley hemochromatosis, and hepatocellular carcinoma Gastroenterology 127 2004 S79 S86
234. C. Borgna-Pignatti, G. Vergine, T. Lombardo, M.D. Cappellini, P. Cianciulli, A. Maggio, D. Renda, M.E. Lai, A. Mandas, G. Forni, A. Piga, and M.G. Bisconte Hepatocellular carcinoma in the thalassaemia syndromes Br. J. Haematol. 124 2004 114 117
235. K.S. Ruccione, K. Mudambi, R. Sposto, J. Fridey, S. Ghazarossian, and D.R. Freyer Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors Pediatr. Blood Cancer 59 2012 697 702
236. O. Kakhlon, and Z.I. Cabantchik The labile iron pool: characterization, measurement, and participation in cellular processes Free Radic. Biol. Med. 33 2002 1037 1046
237. M.M. Hudson, K.K. Ness, J.G. Gurney, D.A. Mulrooney, W. Chemaitilly, K.R. Krull, D.M. Green, G.T. Armstrong, K.A. Nottage, K.E. Jones, C.A. Sklar, D.K. Srivastava, and L.L. Robison Clinical ascertainment of health outcomes among adults treated for childhood cancer JAMA 309 2013 2371 2381
238. M. Tukenova, I. Diallo, H. Anderson, M. Hawkins, S. Garwicz, R. Sankila, C. El Fayech, D. Winter, C. Rubino, E. Adjadj, N. Haddy, O. Oberlin, T. Moller, F. Langmark, L. Tryggvadottir, H. Pacquement, G. Svahn-Tapper, and F. de Vathaire Second malignant neoplasms in digestive organs after childhood cancer: a cohort-nested case-control study Int. J. Radiat. Oncol. Biol. Phys. 82 2012 e383 e390
239. J. Sripetchwandee, N. Pipatpiboon, N. Chattipakorn, and S. Chattipakorn Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity PLoS One 9 2014 e85115
240. I. Pichler, M.F. Del Greco, M. Gogele, C.M. Lill, L. Bertram, C.B. Do, N. Eriksson, T. Foroud, R.H. Myers, PD GWAS Consortium, M. Nalls, M.F. Keller, International Parkinson's Disease Genomics Consortium, Wellcome Trust Case Control Consortium 2, B. Benyamin, J.B. Whitfield, Genetics of Iron Status Consortium, P.P. Pramstaller, A.A. Hicks, J.R. Thompson, and C. Minelli Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study PLoS Med 10 2013 e1001462
241. M. Pandolfo, and L. Hausmann Deferiprone for the treatment of Friedreich's ataxia J. Neurochem. 126 Suppl. 1 2013 142 146
242. C. Moreau, and D. Devos Iron chelation for diseases of regional siderosis Blood 122 2013 3435